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Pharmacogenetics of drug transporters in the
enterohepatic circulation
Abstract
This article summarizes the impact of the pharmacogenetics of drug transporters expressed in
the enterohepatic circulation on the pharmacokinetics and pharmacodynamics of drugs. The
role of pharmacogenetics in the function of drug transporter proteins in vitro is now well
established and evidence is rapidly accumulating from in vivo pharmacokinetic studies, which
suggests that genetic variants of drug transporter proteins can translate into clinically relevant
phenotypes. However, a large amount of conflicting information on the clinical relevance of
drug transporter proteins has so far precluded the emergence of a clear picture regarding the
role of drug transporter pharmacogenetics in medical practice. This is very well exemplified
by the case of P-glycoprotein (MDR1, ABCB1). The challenge is now to develop
pharmacogenetic models with sufficient predictive power to allow for translation into drug
therapy. This will require a combination of pharmacogenetics of drug transporters, drug
metabolism and pharmacodynamics of the respective drugs.
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Summary 
This review summarizes the impact of pharmacogenetics of drug transporters expressed in the 
enterohepatic circulation on pharmacokinetics and pharmacodynamics of drugs. The role of 
pharmacogenetics in the function of drug transport proteins in vitro is now well established 
and evidence is rapidly accumulating from in vivo pharmacokinetic studies that genetic 
variants of drug transport proteins can translate into clinically relevant phenotypes. However, 
a lot of conflicting information on the clinical relevance of drug transport proteins has so far 
precluded the emergence of a clear picture on the role of drug transporter pharmacogenetics in 
medical practice. This is very well exemplified by the case of p-glycoprotein (MDR1, 
ABCB1). The challenge is now to develop pharmacogenetic models with a sufficient 
predictive power for translation into drug therapy. This will require a combination of 
pharmacogenetics of drug transporters, drug metabolism and pharmcodynamics of the 
respective drugs. 
 
1. INTRODUCTION 
Orally administered drugs have to pass several anatomical and functional barriers 
before they reach their targets. These barriers include the uptake across the intestinal wall, the 
passage through the liver as well as the passage through other organ barriers such as for 
example the blood brain barrier or the blood testis barrier [1-3]. After their action, drugs are 
eliminated from the body via the liver or the kidney with or without prior biotransformation 
[4]. Hence, throughout their entire life-span in the body, drugs need to cross cell membranes 
multiple times. Biological membranes are very tight barriers for most molecules and even 
limit the crossing of lipophilic substances such as cholesterol or long chain-fatty acids. This 
latter point is illustrated by the observations that Nieman-Pick C1-like 1 protein is located in 
the apical membrane of enterocytes and involved in cholesterol absorption [5] or that uptake 
of very long-chain fatty acids into peroxisomes involves the role of the ATP binding cassette 
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(ABC) transporter ABCD1 [6] (see table 1 for a list of transporters and their subcellular 
expression covered in this review). The number of drug transporters is high and the 
knowledge on their pharmacogenetics is rapidly evolving [7-15]. 
This review focuses on drug transporters in the enterohepatic circulation, as the 
intestine and the liver are two key organs in drug disposition (figure 1). The prototypic, 
endogenous substrates of the enterohepatic circulation are bile salts [16-18]. Bile salts are bile 
acids conjugated with taurine or glycine. They are secreted by hepatocytes into primary bile 
and shipped via the bile duct into the duodenum, where they promote absorption of lipids and 
fat soluble vitamins. Along the intestinal tract, bile salts are reabsorbed to greater than 95 % 
and shipped back via the portal circulation to the liver, where they are again taken up into 
hepatocytes. A small portion of bile salts is deconjugated in the intestine and reconjugated in 
hepatocytes. Therefore, bile salts can be considered model substances for drugs undergoing 
enterohepatic circulation [19]. 
Drugs taken up into hepatocytes may be excreted into bile either unchanged or as 
biotransformed metabolites and delivered to the intestine. For example, pravastatin is a 
substrate of organic anion transporting polypeptides (OATPs) and of the multidrug resistance 
associated protein 2 (MRP2), which are expressed in the basolateral and canalicular 
membrane of hepatocytes, respectively [20, 21]. Hence, in the liver pravastatin is vectorially 
excreted bile and in the intestine biliary excreted pravastatin is reabsorbed and, thus subjected 
to enterohepatic circulation. Another example is mycophenolic acid, which is widely used as 
an immunosuppressant in solid organ transplantation. Mycophenolate's pharmacokinetic is 
affected by hepatic and renal impairment [22]. It is glucuronidated in different organs 
including the liver into its pharmacologically inactive form 7-O-mycophenolate-glucuronide. 
Recently, it has been demonstrated that the glucuronide of mycophenolate, but not the parent 
compound, is a substrate of OATP1B1 expressed at the basolateral membrane of hepatocytes 
(figure 1)[23]. This metabolite is excreted into bile via rat Mrp2 (and therefore likely also via 
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human MRP2) [24]. In the intestine, the metabolite is deconjugated and mycophenolate is 
taken up again. This enterohepatic recycling may contribute to about 40 % of mycophenolate 
exposure [22]. Interruption of the enterohepatic circulation can also help to control toxicity of 
drugs such as phenprocumon [25, 26], further supporting the clinical importance of 
enterohepatic drug circulation.  
 
2. DRUG TRANSPORTERS IN THE INTESTINE 
Enterocytes are protected from the luminal contents of the intestine by a layer of 
mucus and by a glycocalix, which overlays directly the microvilli of enterocytes [27]. The 
glyocalix is the first boundary, which drugs have to cross prior to their access to the brush 
border membrane of enterocytes. Altered composition of the glycocalix has been 
demonstrated in a rat model to influence the absorption of drugs such as for example 
acetamide [28]. In addition, intestinal absorption in patients receiving chemotherapy is altered 
in part due to a change of the glycocalix [29]. The glyocalix is rich in fixed negative charges, 
which in turn lead to an acidic microenvironment [30] and an increase in the local 
concentration of sodium ions [31]. Hence, the specific local environment facing the brush 
border of enterocytes may potentially impact drug uptake [32], for example by changing the 
hydrophobicity of drugs containing carboxylic acid groups. So far, to the best of our 
knowledge, the pharmacogenetics of the intestinal glycocalix has not been investigated. 
Drug transporters are expressed at distinct levels in different parts of the intestine and 
involve members of the solute carrier (SLC) super family as well as members of the ATP-
binding cassette (ABC) transporter superfamily [10, 33-35]. In the human intestine SLC 
superfamily members include the uptake transporters, CNT1, CNT2, OAT2, OATP1C1, 
OATP2B1, OATP3A1, OATP4A1, OATP4B1, OCT1, OCT3, OCTN1, OCTN2, MCT1, 
MCT2, PEPT1, PEPT2 (table 1) [35-40]. Unfortunately, many studies are based only on 
mRNA expression leaving the subcellular localization and surface distribution of the 
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respective transporters unknown (table 1). The situation is further complicated by the fact that 
antibodies and immunohistochemical procedures used for subcellular transporter localization 
have often not been validated [41], which has lead to conflicting results as for example in the 
case of OATP1A2. While one group found intestinal expression of OATP1A2 [42], other 
groups could not detect it in the human intestine [36, 38, 39]. In addition, although several 
different ABC transporters such as ABCG2, MDR1, MRP1-7 [10, 33-35, 37, 38, 43] have 
been reported to be expressed in human intestine (table 1), the exact subcellular localization 
of many of these transporters has not been worked out. 
PEPT1, MDR1, MRP2 and ABCG2 have definitively been assigned to the brush 
border (apical) plasma membrane domain [33], while MRP3 is expressed at the basolateral 
membrane of enterocytes (figure1 ; table 1). PEPT1 mediates for example the absorption of β-
lactam antibiotics, angiotensin converting enzyme inhibitors, and antiviral drugs among 
others [44]. In contrast, apical MDR1, MRP2 and ABCG2 act as efflux systems and actually 
prevent the entry of their substrates into enterocytes thus reducing the systemic bioavailability 
of their substrates [35]. This has been exemplified in an elegant study for the MDR1 substrate 
digoxin in humans [45]. MDR1 transports a wide variety of xenobiotics including anticancer 
drugs, antifungals, antihistamines, antihypertensives, drugs acting in the central nervous 
system, cardiovascular drugs, HIV-1 protease inhibitors and various immunosuppressants [12, 
35, 43, 46-48]. The general theme of MDR1 substrates is that they are structurally unrelated 
but are either neutral or positively charged hydrophobic compounds. MDR1 has a rather large 
pocket for binding its substrates explaining the large variety of substances that it can 
accommodate [49]. MRP2 mediates efflux of non-metabolized drugs, xenobiotics and of 
numerous phase II metabolites [8, 43, 50, 51]. ABCG2 substrates include a long list of 
chemotherapy agents, antiviral drugs, statins, calcium channel blockers, steroid metabolites 
and toxins such as aflatoxin and ochratoxin A [52-54]. Very interestingly, urate has been 
identified as a possible transport substrate of ABCG2 [55] in a genome wide association study 
 6
aimed at the identification of susceptibility genes for gout [56]. MRP3 seems to transport 
predominantly drug metabolites as well as methotrexate [57]. 
 
3. DRUG TRANSPORTERS IN THE LIVER 
The liver is an essential organ for detoxification and drug metabolism and is situated 
between the intestine and the systemic circulation (figure 1). Consequently, it is equipped 
with an array of uptake systems for drugs and xenobiotics in the basolateral plasma membrane 
of hepatocytes, which are in contact with the blood plasma via the space of Disse and the 
fenestrated endothelium of the sinusoids (table 1, figure 1). These hepatocytic uptake 
transporters belong mostly to the SLC superfamily, which have a major impact on the first 
pass clearance of drugs. The transporters include OATP1B1, OATP1B3, OATP2B1, OAT2 
and OAT7 for anionic compounds and OCT1, OCT3, OCTN1 and OCTN2 for cationic 
compounds [4, 35, 38, 50, 58-60](table 1). Typical drugs transported by OATPs are relatively 
lipophilic anionic drugs such as statins, antibiotics, sartans, angiotensine converting enzyme 
inhibitors and anticancer drugs [61]. OATs also mediate transport of more hydrophilic anionic 
drugs including angiotensin converting enzyme inhibitors, diuretics,, antibiotics, antiviral 
drugs, histamine receptor 2 blockers and nonsteroidal anti-inflammatory drugs [62] Typical 
drug classes handled by the organic cation transporters are anaesthetics, antiallergics, 
antiarythmics, antidepressants, antihypertensives, non steroidal anti-inflammatory drugs, 
antimalarials and antineoplastics [63]. In addition, there are some nucleoside transporters 
expressed in human liver such as CNT1, ENT1 and ENT2 [4, 35, 38, 40, 60, 64]. These 
transporters are highly relevant in treatment of viral hepatitis with nucleoside analogues [65]. 
Finally, NTCP, which predominantly transports glycine and taurine conjugated bile salt 
uptake system, and to a lesser degree also some drugs such as for example rosuvastatin [18]. 
Once the drugs have been biotransformed in the liver, the corresponding metabolites 
have to be eliminated from hepatocytes. This is achieved on one hand by the basolateral 
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export pumps MRP3 and MRP4, which direct their hydrophilic substrates towards renal 
elimination and on the other hand by a variety of canalicular excretory systems, which excrete 
more lipophilic drugs and drug metabolites into bile and direct them towards fecal elimination 
(table 1, figure 1) [35, 38, 43, 50, 66]. MRP3 and MRP4 export, in addition to endogenous 
substrates, mainly drug metabolites and some antimetabolites [57]. MRP6, which is also 
expressed in the basolateral hepatocyte membrane does not seem to be involved in the 
transport of drugs or their metabolites [67]. In fact, the exact physiologic function of MRP6 
has remained elusive so far [68]. At the canalicular membrane MDR1, which is restricted to 
the canalicular membrane of hepatocytes, mediates the export of neutral and cationic 
compounds into bile [4, 35, 38, 66]. Recently, a new canalicular drug transporter called 
multidrug and toxin extruder (MATE) has been identified [69]. The exact role of MATE1 for 
biliary drug elimination needs to be worked out in more details, but it may be involved in 
handling of antiarrhythmics, antibacterials and antimalarials [63]. MRP2 represents the main 
biliary export pump for phase II drug conjugates [70] and ABCG2 has been shown to be 
involved in the biliary elimination of some anticancer drugs [54]. Finally, the canalicular bile 
salt export pump BSEP is a crucial "bottle neck" for biliary secretion of conjugated bile salts 
[18, 71]. So far, only the statin pravastatin has been identified as BSEP substrate [18, 72]. 
However, BSEP is inhibited by a great variety of drugs and, thus, plays a crucial role in the 
pathogenesis of drug induced cholestatic liver disease [18, 73-75]. MRP3 mediates biliary 
phospholipid secretion [76], ABCG5/ABCG8 facilitates canalicular cholesterol release [77] 
and the p-type ATPase ATP8B1 is essential for canalicular bile formation and probably acts 
as an animophospholipid flipase [78]. None of these latter transporters has been shown to be 
involved in drug and/or drug metabolite transport. 
 
4. PHARMACOGENETICS OF INTESTINAL DRUG TRANSPORTERS 
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In the following, the pharmacogenetics of only those transporters that have been 
clearly localized at the subcellular level will be covered. These transporters include PETP1, 
MDR1, MRP2 and ABCG2, which are localized on the apical (luminal) and MRP3 that is 
expressed on the basolateral (blood faced) side of enterocytes and/or hepatocytes (table 1, 
figure 1). The functional consequences in vitro if the various transporter polymorphisms are 
summarized in table 2. Table 3 gives a specific overview about the in vivo consequences of 
MDR1 polymorphisms. To our knowledge, so far no studies on the impact of SLC28 or 
SLC29 family members on pharmacogenetics of drugs have been published. Therefore, these 
transporters are not covered here, but the impact of their genetic variants in in vitro functional 
assays has been reviewed [79]. 
 
4.1. Apical Intestinal Drug Transporters 
PEPT1 (SLC15A1): 
Using a PCR based sequencing approach, 57 genetic variations in SLC15A1 from 48 
unrelated Japanese individuals were identified [80]. Among these, 51 were single nucleotide 
polymorphisms (SNPs) including two nonsynonymous (p.G419A and p.V459I). However, no 
functional assays were reported. The analysis of 44 ethnically different individuals identified 
13 SNPs, of which nine were nonsynonymous [81]. They were functionally characterized in 
HeLa cells and only p.P586L affected the transport capacity of PEPT1 (table 2). Interestingly, 
similar to the Japanese cohort mentioned above, the SNPs p.G419A and p.A449 were also 
found in this study. In another study, 247 ethnically variable individuals displayed 38 SNPs 
[82]. Eight of the nine nonsynonymous variants were expressed in CHO cells, but only 
p.F28Y displayed reduced transport activity (increased Km), while the others remained 
unchanged. To our knowledge, so far no clinical studies have investigated the impact of these 
polymorphisms on the pharmacokinetics of PEPT1 substrates [33]. 
MDR1 (ABCB1): 
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Due to its location in the apical or brush border membrane of enterocytes, MDR1 can 
have a great impact on the bioavailability of certain drugs [35, 83-85]. Consequently, MDR1 
has high clinical relevance in drug therapy and the impact of genetic polymorphisms of 
ABCB1 on drug disposition as well as drug efficacy has been studied extensively and covered 
in multiple reviews [10, 12, 46-48, 86-92]. Overall, more than 50 polymorphisms, 
insertions/deletions and changes in the promoter region have been reported for ABCB1 
encoding MDR1 [12, 48, 93]. A series of nonsynonymous polymorphic variants have been 
characterized functionally. As indicate in table 2, even identical genetic MDR1 variants lead 
to different functional activities in different expression and/or assay systems, illustrating the 
importance of the types of experimental approaches used such as for example direct transport 
measurements or indirect measurements of extrusion of chemically modified MDR1 
substrates. Among the reported polymorphisms, c.1236C>T (synonymous), c.2677G>T/A, 
and c.3435C>T (synonymous) are common with frequencies of 0.41, 0.42/0.02 and 0.54 and 
do not display a distinct pattern in various ethnic groups [12, 47, 48]. They are in strong 
linkage equilibrium. The C.1236T/2677T/3435T haplotype was found in 32 % of Caucasians, 
27 % of Asian-Americans, 35 % Mexican-Americans and 33 % in Pacific-Islanders (ranging 
from 100 to 6 individuals), but only in 5 % of African Americans (99 individuals) [94] as well 
as in 69 % an Ashkenazi Jewish population (101 individuals) [95]. Among these three 
polymorphisms, the c.2677G>T/A (p.A893S/T) is nonsynonymous but its effects on MDR1 
transport function are inconsistent between various studies (table 2) [48, 93]. The 
synonymous c.3435C>T polymorphism has been associated with lower MDR1 protein 
expression [96] and has been extensively investigated in vitro and in vivo. The in vitro 
experiments yielded conflicting results but subtle functional changes of its gene product have 
been reported [93]. Similarly, the in vivo studies on drug disposition yielded conflicting 
qualitative and quantitative results, ranging from increased, unchanged to even lowered 
plasma levels of model drugs [10, 46, 48, 90, 91, 97]. It is therefore not surprising that the 
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pharmacodynamic consequences are also highly variable [46]. Several recent meta analyses of 
studies investigating the c.3435C>T polymorphism are listed in table 3. Digoxin 
pharmacokinetics were not affected by c.3435C>T [98] and the response to anticonvulsant 
drugs exhibited also no association with this polymorphism [99, 100]. In contrast, the effects 
on cyclosporine pharmacokinetics are more complex: Overall, there was no effect of the 
c.3435C>T ABCB1 polymorphism on the pharmacokinetic parameters, although the total 
cyclosporine bioavailability (AUC0-12) was slightly reduced (table 3) [101]. Furthermore, the 
c.3435C>T polymorphism was found to be associated with a minimal increase in the risk for 
ulcerative colitis or breast cancer in Caucasians [102-104]. Taken together, the c.3435C>T 
polymorphism does no seem to have a significant impact on drug disposition, nor does it 
appear to cause a significant risk for intestinal disease processes. Several reasons may account 
for the rather negative or at least conflicting findings: First, the ABCB1 gene contains over 50 
haplotypes [94] displaying ethnicity dependent frequencies. Many studies so far are based on 
populations of mixed ethnicities and did not analyse for detailed haplotypes (table 3). Second, 
many MDR1 substrates are also substrates of cytochrome P450 isoenzymes, especially of 
CYP3A4 [105, 106]. Hence, studies analyzing the exact interplay between CYP3A4 
dependent drug metabolism and MDR1 mediated drug transport are needed to better 
distinguish between pharmacogenetics of drug metabolism and pharmacogenetics of MDR1 
transport functions. Third, MDR1 as well as CYP3A4 are both subject to drug-drug 
interactions at their substrates binding sites and, more importantly, are also highly regulated at 
the expression level by drugs, natural products and food components, all of which can exhibit 
a major impact on the bioavailability of MDR1 substrates [45, 107-109]. Both, pregnane-X-
receptor PXR and constitutive androstane receptor CAR control the transcription of ABCB1 
and, hence, the expression of MDR1 [110-113]. These latter factors may indeed have a greater 
impact on the disposition of MDR1 substrates than ABCB1 polymorphisms. Fourth, many of 
the reported studies have limited power for the detection of subtle interindividual changes in 
 11
drug disposition due to limited sample [114, 115]. And fifth, studies related to the impact of 
c.3435C>T polymorphism of ABCB1 on clinical phenotypes have not been replicated in 
independent large cohorts to confirm findings [116]. Thus the definite elucidation of the 
overall significance of most ABCB1 polymorphisms reported so far requires further 
investigations. 
ABCG2 or BCRP (ABCG2) 
ABCG2 encodes BCRP or ABCG2 and is known to display over 50 different 
polymorphic positions [52, 54, 117]. Most of the SNPs have minor frequencies with the 
exception of c.34G>A and c.421C>A, which have an ethnicity dependent frequency of up to 
0.64 and 0.36, respectively [54]. The impacts of these two polymorphisms are summarized in 
table 2. It becomes clear that the results of different investigations vary, which in part may be 
explained by the fact that these polymorphisms also affect the level of expression and exact 
plasma membrane localization of the transport proteins in the model systems used. As for 
ABCB1, the findings of an impact of ABCG2 polymorphisms on pharmacokinetics of drugs or 
outcomes of cancer therapy are contradictory [7, 33, 53]. An example of contradictory 
findings is irinotecan, where, the ABCG2 c.421C>A polymorphism has been reported to be 
associated with an increased incidence of neutropenia in a Japanese cohort of cancer patients 
[118]. Another study reported an association between an intronic polymorphism and severe 
irinotecan induced myelosuppression [119]. In contrast, two further studies did not find any 
association with irinotecan disposition [120, 121], but Han and coworkers found an 
association with response rate and progression-free survival [121]. Although these 
discrepancies are difficult to understand, the might reflect the complex metabolism of 
irinotecan, the wide tissue distribution of ABCG2 and last but not least the limited number of 
patients included in their perspective studies [53, 122]. 
MRP2 (ABCC2) 
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Multiple polymorphisms and mutations in the ABCC2 gene are known [8, 33, 48, 70]. 
As nonfunctional MRP2 leads to the Dubin-Johnson syndrome, a long list of mutations with 
very low frequencies has been published [70]. 11 polymorphisms display ethnicity variations 
in frequency rates [48, 70]. Among the reported SNPs, c.1249G>A, c.2366C>T, c.3542G>T, 
c.3563T>A, c.3972C>T and c4544G>A are nonsynonymous, whereby c.3972C>T is in 
linkage disequilibrium with c.-25C>T and c.4544GA with c.3563T>A. Some of these 
nonsynonymous variants have bee characterized in heterologous expression systems and do 
no show overt changes in activity but they might exhibit reduced protein expression (table 2). 
Studies focusing on the effect of ABCC2 polymorphisms on pharmacokinetics of drugs are 
rare, but they have been associated with alterations of methotrexate and irinotecan disposition 
[8, 48]. For example, in a pharmacokinetic study of high-dose methotrexate treatment of 
pediatric acute lymphoblastic anemia, the c.-24T allele of ABCC2 was associated with 
significantly elevated AUC36-48 in females [123]. This finding illustrates that polymorphisms 
can have gender specific outcomes. The functional consequence of this promoter variant has 
been postulated to be lower protein expression. One study included 67 cancer patients that 
were treated with irinotecan. Apparently lower irinotecan exposure was found in individuals 
with the c.1249A allele of ABCC2. [124]. In addition, polymorphisms of ABCC2 have been 
associated with irinotecan induced side effects such as diarrhea [8, 48]. In a trial with 167 
patients, carriers of the ABCC2*2 haplotype (c.-1549G, c.-1019G, c.-24C, c.1249G, IVS26 
c.-34T, c.3972C) had significantly less diarrhea [125]. Another study with 87 patients found 
an association between an enhanced enterohepatic circulation of the drug mycophenolate with 
the c.-24T allele [126]. Genetic variants of ABCC2 may also affect the detoxification capacity 
of the liver as suggested by a Korean study including 94 cases of toxic hepatitis, mostly due to 
herbal remedies [127]. Other ABCC2 variants might be associated with an increased 
susceptibility to diclofenac induced liver injury [128]. 
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4.2 Basolateral Intestinal Drug Transporters 
MRP3 (ABCC3) 
Numerous intronic and exonic polymorphisms have been published for ABCC3 [7, 
129-132]. The functional consequences of several variants are presented in table 2. With the 
exception of p.S346F and p.S607N, which have almost completely lost their functional 
activity, all other variants display normal or even slightly increased transport function. A 
study investigating the predisposition and treatment outcome in 139 patients (Jews and Arabs) 
in comparison with 217 controls identified the c.-211C>T variant of ABCC3 as a prognostic 
marker for acute myeloid leukemia [133]. In contrast, no association of ABCC3 
polymorphisms could be associated with colon cancer [134]. In 349 Caucasian patients with 
primary lung cancer, c.-211C>T carriers had a significantly worsened progression-free 
survival, if they displayed with small cell lung cancer [135]. Studies investigating the role of 
MRP3 SNPs on drug pharmacokinetics seem to be absent so far. 
 
5. PHARMACOGENETICS OF LIVER DRUG TRANSPORTERS 
Similar to intestinal transporters, this section will only cover those liver transporters, 
the subcellular localization of which has been characterized on the two polar plasma 
membrane domains of hepatocytes (table 1, figure 1). The functional consequences of the 
various polymorphisms are summarized in table 2. Furthermore, the pharmacogenetics of 
transporters that are expressed in the intestine as well as in the liver (e.g. MDR1, MRP2, 
MRP3, ABCG2), have already been summarized in section 4 and, therefore, will not be 
repeated here. 
 
5.1 Basolateral Drug Transporters in Hepatocytes 
OATP1B1 (SCL1B1) 
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The liver is the target organ of statins. They are widely prescribed in medicine, show 
considerable differences in their pharmacokinetic properties and can cause side effects, 
mainly myotoxicity, which are sometimes severe [136-138]. As OATPs are statin 
transporters, the impact of SLCO gene polymorphisms on statin disposition has been 
extensively studied with a focus on SLCO1B1. [8, 137, 139-142]. A first publication on 
SCLO1B1 polymorphisms investigated the functional consequences of 14 nonsynonymous 
polymorphisms identified by sequencing the SLCO1B1 gene in 42 European-Americans and 
22 African-Americans (table 2) [143]. Among these allelic frequencies the variants 
c.388G>A, c.463A>C, c.521T>C, c.G1463G>C and c.2000A>G are rather frequent and 
ethnicity dependent. Some of the investigated protein variants are associated functionally with 
changes in Km, in vmax and/or in altered transport protein expression (table 2). The authors 
also investigated various other complex haplotypes. They found that OATP1B1*1c (p.R153K, 
p.D241N) has normal activity, OATP1B1*3 (p.V82A, p.E156G) exhibits an increased Km 
and reduced plasma membrane expression, OATP1B1*12 (p.V73L, p.D655G), OATP1B1*13 
(p.V82A, p.E156G, p.E667G) has an increased Km and OATP1B1*14 (p.N130D, p.P155T) 
has an unaltered activity if assessed for transport of the endogenous substrate estrone-3-
sulfate [143]. If rifampicin was used as substrate, the same qualitative results were obtained 
[144]. Individuals homozygous for the CC allele of c.521T>C (p.174A) have a significantly 
higher area under the plasma concentration time curve than individuals with a TT allele [141]. 
A common adverse action of statins is myotoxity, which depends on the serum level of statins 
[136, 145]. The association of OATP1B1 with statin myotoxity has been confirmed by a 
recent landmark paper reporting a genome-wide association study with patients on a high dose 
simvastatin regimen (80 mg daily), which associated 60 % of the patients with myopathy to 
the c.521T>C polymorphism of SCLCO1B1 [146]. Very importantly, this association could be 
replicated also in a population of patients on lower daily simvastatin doses (40 mg) [146]. 
Moreover, the 174A variant of OATP1B1 displayed a slight reduction of the cholesterol 
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lowering effect of simvastatin. Hence, the SLCO1B1 polymorphism c.521T>C appears to be 
the most thoroughly documented polymorphism in the area of drug transporter 
pharmacogenetics. Besides statins, a considerable number of additional drugs such as for 
example antidiabetics, anticancer drugs, immunosuppressants, sartans or antibiotics have been 
found to display pharmacokinetic differences for different OATP1B1 phenotypes [8, 60, 147]. 
OATP1B3 (SLCO1B3): 
Fewer polymorphisms of SLCO1B3 have been reported so far (table 2). Some of the 
nonsynonymous variants reduce the transport function of OATP1B3 in vitro (table 2). In a 
study involving 70 renal transplant recipients, a decrease in dose-normalized mycophenolate 
concomitant with an increase of dose-normalized serum mycophenolate glucuronide was 
associated with the SLCO1B3 c.334G-699A haplotype [23]. In vitro expression the c.334T-
699G variant of SLCO1B3 demonstrated a reduced transport capacity. 
OATP2B1 (SLCO2B1): 
Very few polymorphisms of SLCO2B1 have been described [60, 61] Two rather 
frequent polymorphisms were initially shown to be associated with reduced transport activity 
of OAT2B1 for endogenous substrates (table 2), but one polymorphism was later reported to 
have increased drug transport activity [148, 149]. Pharmacokinetically, the c.935G>A 
polymorphism was demonstrated to lower the plasma level of montelukast, which is used for 
treatment of asthma [150], and to affect the sensitivity of OATP2B1 to orange juice [151]. 
The c.1457C>T variant leads to a significant decrease of fexofenadine exposure, which is 
maintained if fexofenadine is coadministered with apple juice [152]. In addition, a 
polymorphism in the promoter of SLCO2B1 has been reported [153]. c.-282G>A in 
homozygous AA carriers leads to a significant elevation of OATP2B1 mRNA associated with 
elevated protein expression in liver biopsies. Based on these findings, it can be expected that 
the absorption of other drugs, which are substrates of OATP2B1 are subject to interindividual 
variability caused by polymorphisms of SLCO2B1. 
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OCT1 (SLC22A1): 
To date, numerous nonsynonymous polymorphisms for SLC22A1 are known (table 2). 
Functional characterization of the variants shows that the spectrum of transport alterations 
ranges from total absence, no change and significant gains of transporter function. These 
functional changes are substrate dependent. In vivo, OCT1 has been intensively investigated 
with respect to metformin pharmacokinetics and pharmacodynamics [60]. Polymorphisms of 
OCT1 including pR61C result in both, higher exposure to metformin in healthy subjects [154] 
and higher glucose and insulin levels under metformin in healthy volunteers [155]. On the 
other hand, p.R61C did not show any association with imatinib treatment responses in patients 
with chronic myeloid leukemia [156]. 
OCT3 (SLC22A3): 
A detailed summary of studies investigating frequencies of OCT3 polymorphisms is 
presented elsewhere [63]. The investigated polymorphisms do either not change the 
phenotype or lead to a reduction of transport activity (table 2) [157]. A clinical study found no 
association between OCT3 polymorphisms and the renal clearance of metformin in vivo 
[158], while another study found a weak association of OCT3 polymorphisms with diabetic 
nephropathy and hypertension [159]. 
OAT7 (SLC22A9): 
So far, no polymorphisms have been described for this transporter. 
MRP4 (ABCC4): 
In a cohort of 48 Japanese, 257 variations were identified in the ABCC4 gene [129]. 
Among them, three nonsynonymous SNPs without functional characterization were observed. 
Later a study in 95 Caucasians reported 74 variations including 10 nonsynonymous ABCC4 
alterations [160]. In this latter study, c.912G>T (p.L304R) and c.2269G>A (p.Q757K) were 
the same as in the Japanese cohort of 2002. Two recent studies investigated the functional 
consequences of 10 variants (table 2) [161, 162]. Most of the changes were minor, with the 
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exception p.G187W, which resulted in a significantly lower protein expression. While direct 
in vivo pharmacokinetic studies investigating the potential impact of MPRP4 variants on drug 
disposition are missing, several studies found associations between MRP4 variants and drug 
concentrations or adverse events. For example, in a study with 30 HIV patients, higher 
intracellular tenofovir diphosphate concentration in peripheral blood mononuclear were cells 
associated with the c.3436G allele of ABCC4 [163]. Furthermore, in a group of 30 patients 
with different ethnicities, the same ABCC4 polymorphism was associated with higher AUC0-
24 and lower renal clearance tenofovir [164], while in another study, no association with 
kidney tubular dysfunction was observed [165]. Event-free survival in acute lymphoblastic 
leukemia of 275 whites associated significantly with the c.-1393T>C variant and with lower 
methotrexate plasma levels, while the c.934A>C variant of MRP4 was associated with lower 
event-free survival and with higher frequency of high-grade thrombocytopenia [166]. 
However, the latter results could not be reproduced in an independent cohort of 519 patients 
[167]. In 403 patients with breast cancer, cyclophosphamide-induced adverse drug reactions 
were associated with ABCC4 polymorphisms [168], and the c.2269A allele of ABCC4 was 
associated with significantly lower white blood cell counts and with higher erythrocyte 
content of 6-thioguanine nucleotide in a cohort of 235 patients suffering from inflammatory 
bowel disease [169]. 
 
5.2 Canalicular Drug Transporters in Hepatocytes 
The polymorphisms of the canalicular drug excretory systems that are also expressed 
in intestinal epithelial cells (e.g. MDR1, MRP2, ABCG2) have already been dealt with in 
section 4 (see above). 
MATE1 (SLC47A1): 
A screen of DNA samples from 272 ethnically diverse individuals identified six 
nonsynonymous and four synonymous variants of SLC47A1 and a screen of 89 Japanese 
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subjects reported 5 nonsynonymous variants of MATE1 [170, 171]. Some of these variants 
have been functionally characterized and showed in general reduced functions (table 2). 
Clinical studies on the in vivo impact of MATE1 variants have appeared only recently. In a 
population of 116 metformin users, the intronic rs2289669G>A was found to be associated 
with a reduction hemoglobin A1c, which was interpreted as a reflection of reduced transport 
activity of this MATE1 variant [172]. In contrast, another study observed no change in renal 
metformin clearance for the same polymorphism [158]. Furthermore, in a stratified group 
with the intronic SLC22A1 rs622342CC alleles, the rs2289669G>A of SLC47A1 was again 
significantly associated with a lower Hemoglobin A1c. 
 
6. Outlook 
The impact of genetic polymorphisms of drug transporters on drug disposition and 
pharmacodynamics as well as toxicodynamics has been documented in numerous 
publications. However, , most association studies included only small numbers of individuals 
and, therefore, reached frequently only marginal statistical significance. Hence, many 
unresolved questions remain with respect to the predictive potential of transporter 
polymorphisms for drug efficacy and/or adverse drug reactions. There are several reasons for 
these remaining discrepancies: First, drug actions as well as toxic effects are not only 
determined by pharmacogenetics of drug disposition, but also by the pharmacogenetics of 
respective drug targets. This is for example exemplified by the efficacy and side effects of the 
anticoagulant drug warfarin, which is influenced by different polymorphisms of the drug 
metabolizing enzyme CYP2C9 and of the warfarin target vitamin K epoxide reductase 
complex subunit 1 [173]. So far, pharmacogenetic studies addressing all aspects, namely 
transport, metabolism and pharmycodynamics of drugs are very infrequent, because they 
require very large patient populations to reach statistical significance and to produce 
meaningful results [116, 174]. Second, in many instances, conclusive pharmacogenetic studies 
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are blurred by the inclusion of multimorbid patients that are dependent on the simultaneous 
intake of multiple drugs (polypharmacy). Third, often the functional effects of individual 
genetic polymorphisms on the transport proteins are rather small and therefore lead to only 
small alterations in the pharmacokinetics in vivo, which again underlines the need for studies 
with large patient populations. Fourth, replication of the findings in several independent large 
cohorts would certainly add confidence to the identified polymorphisms. An fifth, some of the 
mechanistic models for the disposition of individual drugs may be incomplete and preclude at 
this moment practical predictive models. This point can be illustrated by the potentially 
hepatotoxic antibiotic drug flucloxacillin: While a genome-wide association study identified 
an 80-fold increased risk of the HLA-B*5701 genotype for flucloxacillin induced liver injury 
[175], only one out of  500 to 1:1000 patients treated with flucloxacillin will develop liver 
injury [176]. 
Hence, while pharmacogenetics of drug transporters and adverse drug reactions 
produced considerable new biological knowledge and yielded many promising clinical results, 
there is still a long way to go until reliable models for predicting therapeutic outcome and/or 
adverse drug reactions in the general practice of medicine will be reached. 
 
Executive Summary 
• The liver and intestine are the key organs of enterohepatic circulation. 
• Drug disposition requires a distinct set of drug uptake and drug export transporters in 
the intestine and the liver. 
• Proof of concept for an impact of genetic variants of selected drug transporters on 
pharmacodynamics and toxicodynamics has now been established. 
• Pharmacogenetics of some drug transporters has yielded conflicting phenotypic 
results. 
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• Independent repetition of pharmacogenetic studies could help to clarify the uncertain 
cases. 
• Prospective pharmacogenetic studies on therapeutic outcome and/or adverse events are 
needed to strengthen the relevance of this field in clinical application. 
• Development of new models combining pharmacogenetics of drug disposition and 
drug targets is needed to establish the overall predictive potential of pharmacogenetics 
for clinical therapy. 
 
Acknowledgement 
Bruno Stieger is supported by grant # 31003A_124652 from the Swiss National Science 
Foundation. The authors thank Sarah Steinbacher, scientific illustrator at Multimedia and E-
learning Services, University of Zurich, for the design of figure 1. 
 21
 22 
Table 1: Expression and Subcellular Localization of Drug Transporters in Human Small Intestine and Liver 
gene name protein name protein 
abbreviation 
alias mRNA 
expression* 
subcellular protein localization reference 
 uptake transporters      
SLC28A1 concentrative nucleoside 
transporter 
CNT1  intestine 
liver 
enterocytes, apical and lateral 
unknown 
[177] 
[177] 
SLC28A2  CNT2 SPNT1 intestine 
 
liver 
enterocytes, apical and lateral 
unknown 
[177] 
[177] 
SLC29A1 equilibrative nucleoside 
transporter 
ENT1  intestine 
liver 
crypt cells, lateral 
unknown 
[177] 
[177] 
SLC29A2  ENT2  intestine 
liver 
crypt cells, lateral 
hepatocytes, unknown 
[177] 
[177] 
SLC47A1 multidrug and toxin 
extrusion transporter 
MATE1  liver hepatocytes, canalicular [69] 
SLC16A1 monocarboxylate MCT1  intestine unknown [178] 
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transporter liver unknown [179] 
SLC16A7  MCT2  liver unknown [179] 
SLC10A1 Na+/taurocholate 
cotransporting polypeptide 
NTCP LBAT liver hepatocytes, basolateral [180] 
SLC22A6 organic anion transporter OAT2 NLT liver unknown [181] 
SLC22A9  OAT7 UST3,OAT4 liver hepatocytes, basolateral [182] 
SLCO1A2 organic anion transporting 
polypeptide 
OATP1A2 OATP, OAPT-A liver cholangiocytes [183] 
SLCO1B1  OATP1B1 OATP2, OATP-
C, LST-1 
liver hepatocytes, basolateral [184] 
SLCO1B3  OATP1B3 OATP8 liver hepatocytes, basolateral [185] 
SLCO1C1  OATP1C1 OATP-F, OATP-
RP5 
intestine unknown [38] 
SLCO2B1  OATP2B1 OATP-B, OATP-
RP2 
liver hepatocytes, basolateral [186] 
SLCO3A1  OATP3A1 OATP-D, OATP- intestine unknown [36] 
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RP3 liver unknown [36] 
SCLO4A1  OATP4A1 OATP-E, OATP-
RP1 
intestine 
liver 
unknown 
unknown 
[36] 
[36] 
SLCO4B1  OATP4B1 OATP-H intestine unknown [38] 
SLC22A1 organic cation transporter OCT1  liver hepatocytes, basolateral [187] 
SLC22A3  OCT3 EMT intestine 
liver 
unknown 
hepatocytes, basolateral 
[187] 
[187] 
SLC22A4 cation and carnitine 
transporter 
OCTN1 ETT intestine unknown [188] 
SLC22A5  OCTN2 CT1,CDSP intestine unknown [188] 
SLC15A1 peptide transporter PEPT1 PECT1 intestine enterocytes, apical [189] 
SLC15A2  PEPT2  intestine unknown [38] 
       
 export transporters      
ABCG2 ABCG2 ABCG2 BCRP, ABC-P intestine 
liver 
enterocytes, apical 
hepatocytes, canalicular 
[190] 
[190] 
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ABCB1 multi drug resistance 
protein 
MDR1 p-glycoprotein, p-
gp 
intestine 
liver 
enterocytes, apical 
hepatocytes, canalicular 
[191] 
[191] 
ABCC1 multidrug resistance-
associated protein 
MRP1  intestine unknown [192] 
ABCC2  MRP2 cMOAT intestine 
liver 
enterocytes, apical 
hepatocytes, canalicular 
[193] 
[194] 
ABCC3  MRP3  intestine 
 
liver 
enterocytes, basolateral 
hepatocytes, basolateral 
[195] 
[196] 
ABCC4  MRP4  intestine 
liver 
unknown 
hepatocytes, basolateral 
[197] 
[198] 
ABCC5  MRP5  intestine unknown [197] 
AABC6  MRP6  intestine 
liver 
unknown 
hepatocytes, basolateral 
[197] 
[199] 
ABCC10  MRP7  intestine unknown [200] 
 
3) mRNA expression is indicated for tissues or cells with positive mRNA signals. 
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More informations: For members of the SLC superfamily of transporters: www.bioparadigms.org/slc/menu.asp; for ABC transporters 
http://nutrigene.4t.com/humanabc.htm. 
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Table 2: In vitro Functional Characterization of Genetic Drug Transporters Variants in Human Small Intestine and Liver 
gene name transporter single nucleotide 
polymorphism 
protein population size in vitro function reference 
 intestinal uptake 
transporters 
     
SLC15A1 PEPT1  p.P586L 
 
44 individuals 
 
reduced vmax [81] 
 
SLC15A1 PEPT1  p.F28Y 247 individuals increased Km [82] 
 intestinal efflux 
transporters 
     
ABCB1 MDR1 c.571G>A p.G191R n/a reduced drug resistance [201] 
ABCB1 MDR1 c.1199G>A p.S440N n/a reduced activity (substrate dependent) [202] 
ABCB1 MDR1 c.11199G>A 
c.1199G>t 
p.S440N 
p.S440I 
n/a 
n/a 
increased drug resistance 
reduced drug resistance 
[203] 
ABCB1 MDR1 c.1292-3GT>TG p.C431L n/a reduced drug resistance [204] 
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ABCB1 MDR1 c.2005C>T p.R669C n/a reduced substrate affinity [202] 
ABCB1 MDR1 c.2547A>G p.I849M n/a increased transport activity [202] 
ABCB1 MDR1 c.2677G>T p.A893S 60 individuals lower intracellular digoxin accumulation [205] 
ABCB1 MDR1 c.2677G>T 
c.2677G>A 
p.A893S 
p.A893T 
n/a 
n/a 
unchanged 
unchanged 
[206] 
 
ABCB1 MDR1 c.2677G>T p.A893S 46 individuals no change in rhodamine 123 efflux from 
peripheral blood lymphocytes 
[207] 
ABCB1 MDR1 c.2667G>T p.A893S n/a reduced transport function [208] 
ABCB1 MDR1 c.2667G>T 
c.2677G>A 
p.A893S 
p.A.893T 
n/a 
n/a 
increased transport function 
increased transport function 
[209] 
ABCB1 MDR1 c.2667G>T 
 
c.2677G>A 
p.A893S 
 
p.A.893T 
n/a 
 
n/a 
increased activity (substrate dependent) 
increased substrate affinity and transport 
activity 
[202] 
ABCB1 MDR1 c.2667G>T p.893S 48 individuals no change in rhodamine 123 efflux 
activity in peripheral blood mononuclear 
cells 
[210] 
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ABCB1 MDR1 c.2956A>G p.M986V n/a increased transport activity [202] 
ABCB1 MDR1 c.2995G>A p.A999T n/a increased substrate affinity and transport 
activity  
[202] 
ABCB1 MDR1 c.3151C>G p.P1051A n/a increased transport activity (substrate 
dependent) 
[202] 
ABCB1 MDR1 c.3188G>C p.G1063A n/a increased transport activity [202] 
ABCG2 ABCG2 c.34G>A p.V12M n/a low transport protein expression in vitro [211] 
ABCG2 ABCG2 c.34G>A p.V12M n/a unchanged [212] 
ABCG2 ABCG2 c.34G>A p.V12M n/a no change in HEK-293, lowered transport 
activity in Sf9 cells in vitro 
[213] 
ABCG2 ABCG2 c.34G>A p.V12M n/a unchanged [214] 
ABCG2 ABCG2 c.421C>A Q141K n/a lower transport protein expression, 
normal transport activity 
[212] 
ABCG2 ABCG2 c.421C>A Q141K n/a reduced drug resistance and lower 
ATPase activity 
[213] 
ABCG2 ABCG2 c.421C>A Q141K n/a reduced drug extrusion [215] 
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ABCG2 ABCG2 c.421C>A Q141K n/a reduced drug resistance [216] 
ABCG2 ABCG2 c.421C>A Q141K n/a unchanged [217] 
ABCG2 ABCG2 c.421C>A Q141K n/a no change of intracellular porphyrine 
accumulation 
[218] 
ABCG2 ABCG2 c.421C>A Q141K n/a reduced transport activity [219] 
ABCG2 ABCG2 c.421C>A Q141K n/a reduced transport activity [55] 
ABCG2 ABCG2 c.421C>A Q141K n/a increased Km [220] 
ABCC2 MRP2 c.1249G>A p.V417I n/a unchanged [221] 
ABCC2 MRP2 c.1249G>A p.S789F n/a reduced transport protein expression, no 
change in transport activity 
[221] 
ABCC2 MRP2 c.1249G>A p.A1450T n/a reduced transport protein expression, no 
change in transport activity 
[221] 
ABCC3 MRP3 c.32G>A p.G11D n/a unchanged [222] 
ABCC3 MRP3 c.1037C>T p.S346S n/a reduced transport activity [222] 
ABCC3 MRP3 c.1820G>A p.S607N n/a reduced transport activity [222] 
ABCC3 MRP3 c.2293G>C p.V765L n/a unchanged [222] 
 31 
ABCC3 MRP3 c.2758C>T p.P920S n/a unchanged [222] 
ABCC3 MRP3 c.2768G>A p.R923Q n/a increased transport activity [222] 
ABCC3 MRP3 c.3856G>C p.R1286G n/a unchanged [222] 
ABCC3 MRP3 c.3890G>A p.R1297H 52 individuals unchanged [131] 
ABCC3 MRP3 c.4042C>T p.R1348C n/a increased transport activity [222] 
ABCC3 MRP3 c.4094A>G p.Q1365R n/a unchanged [222] 
ABCC3 MRP3 c.4141C>A p.R1381S n/a unchanged [222] 
 liver uptake 
transporters 
     
SLCO1B1 OATP1B1 c.218T>C p.F73L n/a increased Km, reduced protein synthesis 
and membrane expression 
[143] 
SLCO1B1 OATP1B1 c.245T>C p.V82A n/a  [143] 
SLCO1B1 OATP1B1 c.388A>G p.N130D n/a increased Km [143] 
SLCO1B1 OATP1B1 c.455G>A p.R152K n/a  [143] 
SLCO1B1 OATP1B1 c.463C>A p.P155T n/a unchanged [143] 
SLCO1B1 OATP1B1 c.467A>G p.E156G n/a  [143] 
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SLCO1B1 OATP1B1 c.521T>C p.V174A n/a decreased vmax, reduced transport protein 
expression 
[143] 
SLCO1B1 OATP1B1 c.721G>A p.D241N n/a  [143] 
SLCO1B1 OATP1B1 c.1058T>C p.I353T n/a increased Km, reduced transport protein 
expression 
[143] 
SLCO1B1 OATP1B1 c.1294A>G p.N432D n/a decreased vmax [143] 
SLCO1B1 OATP1B1 c.1385A>G p.D462G n/a decreased vmax [143] 
SLCO1B1 OATP1B1 c.1463G>C p.G488A n/a reduced intrinsic clearance, reduced 
transport protein expression 
[143] 
SLCO1B1 OATP1B1 c.1964A>G p.D655G n/a increased Km [143] 
SLCO1B1 OATP1B1 c.2000A>G p.E667G n/a unchanged [143] 
SLCO1B3 OATP1B3 c.334T>G p.S112A n/a unchanged [223, 224] 
SLCO1B3 OATP1B3 c.439A>G p.T147A n/a unchanged [223] 
SLCO1B3 OATP1B3 c.699G>A p.M233I n/a reduced transport activity, substrate 
dependent alteration of Km 
[223, 224] 
SLCO1B3 OATP1B3 c.767G>C p.G256A n/a unchanged [223] 
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SLCO1B3 OATP1B3 c.1559A>G p.H520P n/a reduced transport activity [223] 
SLCO1B3 OATP1B3 c.1564G>T p.G522C n/a reduced transport activity [224] 
SLCO1B3 OATP1B3 c.1679T>C p.V560A n/a reduced transport activity [223] 
SLCO2B1 OATP2B1 c.43C>T p.P15S n/a reduced transport activity [149] 
SLCO2B1 OATP2B1 c.601G>A p.V201M n/a reduced transport activity [149] 
SLCO2B1 OATP2B1 c.1175C>T p.T392I n/a reduced vmax [148] 
SLCO2B1 OATP2B1 c.1457C>T p.S486F n/a reduced vmax 
increased transport activity 
[148] 
[149] 
SLC22A1 OCT1 c.41C>T p.S14F n/a increased TEA transport 
reduced metformin transport 
[225] 
[155] 
SLC22A1 OCT1 c.123C>T     
SLC22A1 OCT1 c.181C>T p.R61C n/a reduced transport activity [225, 226] 
SLC22A1 OCT1 c.253C>T p.L85F n/a unchanged [225] 
SLC22A1 OCT1 c.262C>T p.C88R n/a absent [226] 
SLC22A1 OCT1 c.480G>C p.F160L n/a unchanged [225, 226] 
SLC22A1 OCT1 c.566C>T p.S189L n/a unchanged TEA transport [225] 
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reduced transport activity [155] 
SLC22A1 OCT1 c.659G>T p.G220V n/a absent [225] 
SLC22A1 OCT1 c.848C>T p.P263L n/a absent [227] 
SLC22A1 OCT1 c.859G>C p.R287G n/a absent [227] 
SLC22A1 OCT1 c.1022C>T p.P341L n/a reduced TEA transport 
normal metformin transport 
[225] 
[155] 
SLC22A1 OCT1 c.1025G>A p.R342H n/a unchanged [225] 
SLC22A1 OCT1 c.1201G>A p.G401S n/a no TEA transport 
no MPP transport, reduced TEA transport 
[225] 
[226] 
SLC22A1 OCT1 c.1222A>G p.M408V n/a unchanged [225] 
SLC22A1 OCT1 c.1391G>A p.V461I n/a unchanged [225] 
SLC22A1 OCT1 c.1386-1170G>A p.G465R n/a absent [225] 
SLC22A1 OCT1 c.1386-1100G>T p.R488M n/a unchanged [225] 
SLC22A3 OCT3 c.131C>T p.T44M n/a unchanged [157] 
SLC22A3 OCT3 c.346G>T p.A116S n/a reduced transport activity [157] 
SLC22A3 OCT3 c.1160G>T p.M370I n/a reduced transport activity [228] 
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SLC22A3 OCT3 c.1199C>T p.T400I n/a reduced transport activity [157] 
SLC22A3 OCT3 c.1316C>T p.A439V n/a reduced transport activity [157] 
SLC22A3 OCT3 c.1423G>A pG475S n/a reduced transport activity [157] 
 liver efflux 
transporters 
     
SLC47A1 MATE1 c.28G>T p.V10L n/a unchanged [171] 
SLC47A1 MATE1 c.191G>A p.G64D n/a reduced transport activity, reduced drug 
resistance 
loss of transport activity 
[170] 
 
[171] 
SLC47A1 MATE1 c.373C>T p.L125F n/a reduced transport activity (substrate 
dependent) 
[170] 
SLC47A1 MATE1 c.404T>C p.V159M n/a reduced transport activity [229] 
SLC47A1 MATE1 c.929C>T p.A310V n/a reduced transport activity [171] 
SLC47A1 MATE1 c.983A>C p.D328A n/a reduced transport activity [171] 
SLC47A1 MATE1 c.1012G>A p.V338I n/a reduced transport activity (substrate 
dependent 
[170] 
[229] 
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reduced transport activity 
SLC47A1 MATE1 c.1421A>G p.N474S n/a reduced transport activity [171] 
SLC47A1 MATE1 c.1438G>A p.V480M n/a reduced transport activity, reduced drug 
resistance 
[170] 
SLC47A1 MATE1 c.1490G>C 
C.149G>T 
p.C497S 
p.C497F 
n/a reduced, unchanged or increased transport 
activities (substrate dependent)  
[170, 229] 
SLC47A1 MATE1 c.1557G>C p.Q519H n/a unchanged [170] 
ABCC4 MRP4 c.232C>G p.P78A n/a increased intracellular drug accumulation 
(substrate dependent), lower transport 
protein expression 
[161] 
ABCC4 MRP4 c.559C>T p.G187W n/a increased intracellular drug accumulation, 
reduced transport protein expression 
slightly reduced function 
[161] 
 
 
[162] 
ABCC4 MRP4 c.877A>G p.K293E n/a unchanged [161] 
ABCC4 MRP4 c.912G>T p.K304N n/a unchanged [161] 
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unchanged [162] 
ABCC4 MRP4 c.1208C>T p.P403L n/a increased intracellular drug accumulation [161] 
ABCC4 MRP4 c.1460G>A p.G487E n/a increased intracellular drug accumulation 
reduced transport activity (substrate 
dependent) 
[161] 
 
[162] 
ABCC4 MRP4 c.1492A>G p.K498E n/a unaltered [161] 
ABCC4 MRP4 c.1667A>G p.Y556C n/a increased transport activity [162] 
ABCC4 MRP4 c.2269G>A p.E575K n/a increased transport activity [162] 
ABCC4 MRP4 c.2230A>G p.M744V n/a unchanged [161] 
ABCC4 MRP4 c.2326G>A p.V776I n/a reduced transport activity [162] 
ABCC4 MRP4 c.2459G>T p.R820I n/a reduced transport activity [162] 
ABCC4 MRP4 c.2560G>T p.V854F n/a unchanged [162] 
ABCC4 MRP4 c.2596A>G p.I866V n/a unchanged [162] 
ABCC4 MRP4 c.2867G>C p.C956S n/a reduced intracellular drug accumulation [161] 
ABCC4 MRP4 c.3211G>A p.V1071I n/a unchanged [161] 
ABCC4 MRP4 c.3425C>T p.T1142M n/a increased transport activity [162] 
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For more information on members of the SLC superfamily of transporters please consult www.bioparadigms.org/slc/menu.asp and for more 
information of ABC transporters http://nutrigene.4t.com/humanabc.htm. 
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Table 3: Meta Analyses on the impact in vivo of the c.3435C>T polymorphism of ABCB1on pharmacokinetics, pharmacodynamics and 
susceptibility to various diseases 
 
number of 
studies 
included 
number of individuals study subject outcome reference 
8 out of 11 121 of different ethnicities digoxin 
pharmacokinetics 
no difference in exposure, slight reduction in Cmax -0.31 ng/ml 
CI (-0.59, -0.02) 
[98] 
4 out of 5 135 of different ethnicities MDR1 expression no difference [98] 
7 out 8 2931 controls, 1743 
ulcerative colitis, 2311 
Crohn’s diesease 
relative risk odds ratio for ulcerative colitis 1.12 CI (1.01, 1.23) 
odds ration for Crohn’s disease: 0.99 CI (0.89, 1.10) 
[102]*) 
6 out of 9 2098 controls, 1530 
uilcerative colitis, 1473 
Crohn’s disease 
relative risk odds ratio for ulcerative colitis 1.17 CI (1.06, 1.31) 
no association with Crohn’s Disease 
[103] *) 
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3 out of 7 n/a multidrug resistance in 
epilepsy 
no association [230] 
14 out of 17 1036 of different ethnicities cyclosporine 
pharmacokinetics 
no difference in AUC0-4 and AUC0-inf, AUC0-12 -0.36 
(mg/hr/l)mg/kg CI (-0.67, -0.05), no difference in Cmax 
[101] 
11 out of 12 1725 controls, 1646 patients multidrug resistance in 
epilepsy 
no association [99] 
2 3149 breast cancer patients, 
5489 control 
hormone therapy 
associated breast 
cancer risk 
no association [231] 
9 out of 9 2454 patients, 1542 controls predisposition to 
epilepsy 
no association [232] 
22 3231 drug resistant patients, 
2524 drug responders or 
healthy controls of different 
ethnicities 
multidrug resistance in 
epilepsy 
no association [100] 
8 out of28 3829 cases, 6193 controls of breast cancer risk no risk for Asian, Caucasians OR 1.26 CI (1.04, 1.52) for T [104] 
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different ethnicities versus C 
*) partial overlap of cohorts 
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Figure Legends 
Figure 1: Overview of drug transporters expressed at the membrane boundaries of the 
enterohepatic circulation.
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